The global ADME Toxicology Testing Market size is expected to generate a revenue of USD
10.25 billion by 2025, according to a new report by Grand View Research, Inc.,
exhibiting a CAGR of 11.4% during the forecast period. Factors such as
increased need to check late-stage drug failures with adoption of more
appropriate toxicity testing methods by pharmaceutical companies is expected to
aid revenue generation for the market.
Absorption, distribution,
metabolism, and excretion (ADME) toxicology testing is used to test toxic
reactions caused by molecules in clinical trials on factors and systemic
reactions such as chemical, pharmaceutical, and genetic. These toxicology
testing procedures help in effective drug development, which limits or prevents
toxic reactions to the body when administered. Toxicity levels are decided on
the results of a series of tests conducted in near natural conditions, which
represent almost real-time reactions between the drug and host.
As of 2017, approximately 43.0%
of ADME toxicology testing areas carried out are based on cell culture tech.
Cell culture technology is adopted widely owing to advantages such as near
natural conditions and accurate results obtained at a cellular level.
These assays are conducted for
several types of toxic reactions or systems where toxic reactions might take
place. Some of the toxicity tests are systemic toxicity, renal toxicity,
hepatotoxicity, neurotoxicity, and other toxicities that might result in a
living tissue. Advancements in testing methods are underway and this trend is
likely to be picked up by many companies developing drug molecules. This will
speed up the drug discovery process and boost market growth.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/adme-toxicology-testing-market
Further key findings from the report suggest:
- The market is driven by increasing ratio of
late-stage drug failures, resulting in loss of valuable time and
investment for drug development. Growth and increasing adoption of OMICS
technology is also expected to boost revenue generation in the coming
years
- North America is the largest market for ADME
toxicology testing owing to presence of large number of pharmaceutical companies
competing for commercial launch of novel molecules
- Developing regions of Asia Pacific and Latin
America are set to grow considerably as many multinational and local
players are striving to enter the market. They are also looking improve
their hold in markets that present innovation and growth opportunities
- Some of the key players in this market are
Accelrys Inc.; Agilent Technologies, Inc.; Albany Molecular Research Inc.;
Beckman Coulter Inc.; Catalent Inc.; Charles River Laboratories
International Inc.; AbbVie; Actelion Pharmaceuticals; Amgen; Biocon; BioMarin;
Boehringer Ingelheim; Bristol-Myers Squibb; Cipla; and CymaBay
Therapeutics.
No comments:
Post a Comment